Category Archives: On-Sale Bar

DC denial of on-sale bar defense reversed; claim construction affirmed; grant of enhanced damages reversed based on attorney opinion; reasonably royalty affirmed

Sunoco Partners Marketing & Terminals, L.P. v. U.S. Venture, Inc. et al. (“Venture”) Docket No. 2020-1640, -1641 (https://cafc.uscourts.gov/opinions-orders/20-1640.OPINION.4-29-2022_1943607.pdf) PROST, REYNA, STOLL April 29, 2022 Brief Summary:  DC denial of on-sale bar defense reversed; claim construction affirmed; grant of enhanced damages … Continue reading

Posted in Claim Construction, Claim Differentiation, Damages, Experimental Use, Expert Testimony, Infringement, Lost Profits, On-Sale Bar, Royalties, Willfullness | Leave a comment

DC grant of no invalidity of design patent reversed due to pre-critical date offer for sale

Larry K. Junker v. Medical Components, Inc., Martech Medical Products, Inc. Docket No. 2021-1649 (https://cafc.uscourts.gov/opinions-orders/21-1649.OPINION.2-10-2022_1906548.pdf) DYK, REYNA, STOLL February 10, 2021 Brief Summary:  DC decision finding no invalidity of design patent for invalidity due to pre-critical date offer for sale … Continue reading

Posted in Anticipation (35 USC 102), Design Patents, On-Sale Bar | Leave a comment

Prior knowledge or use, public use, and on-sale bar holdings reversed (e.g., must be accessible to the public)

BASF Corp. v. SNF Holding Company, et al. Docket No. 2019-1243 LOURIE, REYNA, HUGHES April 8, 2020 Brief Summary: DC decisions finding prior knowledge or use, public use, and on-sale bar reversed and remanded. Summary: BASF appealed DC decision granted … Continue reading

Posted in Anticipation (35 USC 102), On-Sale Bar, Public Accessibility, Public Use | Leave a comment

Failure to disclose pre-critical date offer for sale was inequitable conduct, DC decision affirmed

GS Cleantech, Cantor Colburn LLP v. Adkins Energy LLC, Big River Resources et al. Docket No. 2016-2231, -1838, 2017-1832 REYNA, WALLACH, HUGHES March 2, 2020 Brief Summary: DC finding of inequitable conduct for failure to disclose pre-critical date offer for … Continue reading

Posted in Inequitable Conduct, On-Sale Bar, Uncategorized | Leave a comment

Federal Circuit reverses DC grant of SJ based on § 102(b) on-sale bar defense (e.g., inventor declarations not “sham affidavits”)

Quest Integrity USA, LLC v. Cokebusters USA Inc. Docket No. 2017-2423 DYK, TARANTO, HUGHES May 21, 2019 Brief summary: DC grant of SJ based on § 102(b) on-sale bar defense (e.g., inventor declarations not “sham affidavits”) reversed. Summary: Quest appealed … Continue reading

Posted in Anticipation (35 USC 102), On-Sale Bar, Prosecution History Estoppel | Leave a comment

Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc. et al.

Docket No. 2016-1284, -1787 DYK, MAYER, O’MALLEY May 1, 2017 (FC panel); June 25, 2018 (SCOTUS); Jan. 24, 2019 (SCOTUS) Update 2 (Jan. 24, 2019): Update 2 (Jan. 24, 2019): SCOTUS affirmed the FC panel decision, holding that “a commercial … Continue reading

Posted in Anticipation (35 USC 102), On-Sale Bar | Leave a comment

Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc. et al.

SCOTUS Docket No. 17-1229 FC Docket No. 2016-1284, -1787 DYK, MAYER, O’MALLEY May 1, 2017 Brief Summary: In its May decision, an FC panel reversed the DC and found the asserted claims invalid under the § 102(b) on-sale bar, the … Continue reading

Posted in On-Sale Bar | Leave a comment

The Medicines Company v. Hospira, Inc.

Docket No. 2014-1469, -1504 DYK, WALLACH, HUGHES February 6, 2018 Brief summary: DC’s decision that distribution agreement was not an offer for sale reversed as the agreement “make[s] clear that [MedCo] and ICS entered into an agreement to sell and … Continue reading

Posted in Claim Construction, Infringement, On-Sale Bar | Leave a comment

Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc. et al.

Docket No. 2016-1284, -1787 DYK, MAYER, O’MALLEY May 1, 2017 Brief Summary: FC panel reversed DC and found the asserted claims invalid under the § 102(b) on-sale bar. The FC panel concluded that the AIA did not change the meaning … Continue reading

Posted in America Invents Act, Anticipation (35 USC 102), Generics / ANDA, On-Sale Bar | Leave a comment

The Medicines Company (“MedCo”) v. Hospira, Inc.

Docket No. 2014-1469, -1504 En banc opinion July 11, 2016 Brief Summary: En banc opinion concluded “a product produced pursuant to the claims of a product-by-process patent is ‘on sale’ under 35 U.S.C. § 102(b)…must be the subject of a … Continue reading

Posted in Anticipation (35 USC 102), On-Sale Bar | Leave a comment